drugset / Trial / NCT03012386
CD36 in Nutrient Delivery and Its Dysfunction
Phase 1/2
Completed
26 enrolled
Vanderbilt University Medical Center
Washington University School of Medicine · collab
NaSingle-groupOpen-labelBasic science
Summary
This proposal will test the hypothesis that chronic treatment with sildenafil with and without the use of nitric oxide substrate, L-arginine, protects against fatty acid induced impairment of endothelial function, improves insulin-stimulated microvascular recruitment, insulin sensitivity and glucose uptake in CD36 rs3211938 G-allele carriers.
Timeline
- Start
- 2017-01
- Primary completion
- 2021-07
- Completion
- 2021-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sildenafil | Unknown | 20 mg | — |
Indications
No indication recorded.